ABL1 is altered in 1.58% of malignant hepatobiliary neoplasm patients [2].

ABL1 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is altered in 4.1% of malignant hepatobiliary neoplasm patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

DDR2 is altered in 1.54% of malignant hepatobiliary neoplasm patients [2].

DDR2 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is altered in 2.5% of malignant hepatobiliary neoplasm patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

EPHA2 is altered in 0.28% of malignant hepatobiliary neoplasm patients [2].

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is altered in 4.02% of malignant hepatobiliary neoplasm patients [2].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB4 is altered in 2.16% of malignant hepatobiliary neoplasm patients [2].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is altered in 1.49% of malignant hepatobiliary neoplasm patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 is altered in 6.57% of malignant hepatobiliary neoplasm patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 is altered in 1.35% of malignant hepatobiliary neoplasm patients [2].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 is altered in 1.81% of malignant hepatobiliary neoplasm patients [2].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FRK is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FRK status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 is altered in 9.52% of malignant hepatobiliary neoplasm patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KDR is altered in 2.3% of malignant hepatobiliary neoplasm patients [2].

KDR is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KDR status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is altered in 1.39% of malignant hepatobiliary neoplasm patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK11 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is altered in 1.08% of malignant hepatobiliary neoplasm patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is altered in 1.33% of malignant hepatobiliary neoplasm patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 is altered in 0.5% of malignant hepatobiliary neoplasm patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RET is altered in 1.65% of malignant hepatobiliary neoplasm patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RET status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

TEK is altered in 0.57% of malignant hepatobiliary neoplasm patients [2].

TEK is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TEK status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFA is altered in 1.7% of malignant hepatobiliary neoplasm patients [2].

VEGFA is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC is an inclusion eligibility criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].